Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced the introduction of Hu-mAtrIx, an innovative AI-assisted drug discovery engine. This platform marks a significant advancement in the field of antibody development, leveraging cutting-edge technology to enhance efficiency and success rates.
Integrated Antibody Discovery Platform
Nona’s Hu-mAtrIx platform enables a fully integrated antibody discovery process, ranging from protein design and single-cell based antibody screening to next-generation sequencing, antibody modeling, and engineering. By incorporating AI and automation technologies, Hu-mAtrIx significantly shortens discovery timelines and improves the overall success rate of antibody drug development.
Key Features and Benefits
Hu-mAtrIx offers integrated solutions to identify optimal antibodies with high efficiency. The platform allows for the exploration of large libraries of human antibody sequences to pinpoint those with the desired target specificity and binding affinity. Additionally, it predicts critical antibody properties such as stability, manufacturability, and immunogenicity, thereby mitigating development risks in the early stages of discovery.
Expansion of Core Technology
Nona Biosciences is further enhancing its capabilities by developing a new AI model to expand its core technology platform, HCAb Plus. This new model builds on the unique capabilities of its HCAb Harbour Mice, the industry’s leading fully human heavy-chain-only transgenic mouse platform, and its proprietary HCAb dataset. This advancement pushes the boundaries of antibody discovery, enabling the identification of rare, highly specific antibodies with greater precision and efficiency.-Fineline Info & Tech
Leave a Reply